MX2019007021A - Anticuerpos il-11ra. - Google Patents

Anticuerpos il-11ra.

Info

Publication number
MX2019007021A
MX2019007021A MX2019007021A MX2019007021A MX2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A
Authority
MX
Mexico
Prior art keywords
antibodies
disclosed
compositions
methods
Prior art date
Application number
MX2019007021A
Other languages
English (en)
Inventor
Alexander Cook Stuart
Schaefer Sebastian
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of MX2019007021A publication Critical patent/MX2019007021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Abstract

Se divulgan los anticuerpos IL-11Ra. Tambien se divulgan son composiciones que comprenden anticuerpos IL-11Ra y los metodos de uso de anticuerpos IL-11Ra.
MX2019007021A 2016-12-16 2017-12-15 Anticuerpos il-11ra. MX2019007021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621439.7A GB201621439D0 (en) 2016-12-16 2016-12-16 IL-11Ra Antibodies
PCT/EP2017/083043 WO2018109170A2 (en) 2016-12-16 2017-12-15 Il-11ra antibodies

Publications (1)

Publication Number Publication Date
MX2019007021A true MX2019007021A (es) 2019-10-21

Family

ID=58284610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007021A MX2019007021A (es) 2016-12-16 2017-12-15 Anticuerpos il-11ra.

Country Status (12)

Country Link
US (2) US20180186872A1 (es)
EP (1) EP3555135B1 (es)
JP (1) JP7175271B2 (es)
KR (1) KR20190111924A (es)
CN (1) CN110337447B (es)
AU (1) AU2017378107A1 (es)
BR (1) BR112019012343A2 (es)
CA (1) CA3046848A1 (es)
GB (1) GB201621439D0 (es)
MX (1) MX2019007021A (es)
TW (1) TW201829465A (es)
WO (1) WO2018109170A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
EP3555131A2 (en) 2016-12-16 2019-10-23 Singapore Health Services Pte Ltd Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
MX2021013356A (es) 2019-05-03 2022-03-11 Singapore Health Serv Pte Ltd Tratamiento y prevencion de enfermedades metabolicas.
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CA3199586A1 (en) * 2020-11-23 2022-05-27 Samantha J. Busfield Antigen-binding molecules and uses thereof
CA3211686A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN113735975B (zh) * 2021-09-07 2022-08-12 广东东阳光药业有限公司 一种抗il-11r抗体及其应用
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
WO2023143590A1 (zh) * 2022-01-29 2023-08-03 迈威(上海)生物科技股份有限公司 采用抗il-11抗体的肿瘤组合疗法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797664B1 (en) 1994-12-22 2006-10-18 Genetics Institute, LLC Use of a human interleukin-11 receptor
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
CN1688293A (zh) 2002-09-16 2005-10-26 韦思公司 多肽治疗剂口服给药的缓释配方及其使用方法
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
EP1957097A1 (en) 2005-12-06 2008-08-20 Wyeth a Corporation of the State of Delaware Interleukin-11 compositions and methods of use
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
WO2008050789A1 (fr) 2006-10-27 2008-05-02 The New Industry Research Organization Utilisation de l'interleukine-11 en tant qu'agent thérapeutique pour une cardiopathie
US7993637B2 (en) 2007-10-26 2011-08-09 Csl Limited IL-11 muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CN104995211B (zh) * 2013-02-07 2019-09-13 Csl有限公司 Il-11r结合蛋白及其应用
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
EP3555131A2 (en) 2016-12-16 2019-10-23 Singapore Health Services Pte Ltd Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
JP2020513745A (ja) 2020-05-21
CA3046848A1 (en) 2018-06-21
EP3555135A2 (en) 2019-10-23
US11078269B2 (en) 2021-08-03
KR20190111924A (ko) 2019-10-02
GB201621439D0 (en) 2017-02-01
BR112019012343A2 (pt) 2019-11-26
CN110337447A (zh) 2019-10-15
US20180186872A1 (en) 2018-07-05
WO2018109170A2 (en) 2018-06-21
EP3555135B1 (en) 2024-04-10
CN110337447B (zh) 2023-05-26
TW201829465A (zh) 2018-08-16
US20200207847A1 (en) 2020-07-02
AU2017378107A1 (en) 2019-07-25
WO2018109170A3 (en) 2018-08-30
JP7175271B2 (ja) 2022-11-18

Similar Documents

Publication Publication Date Title
MX2019007021A (es) Anticuerpos il-11ra.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007020A (es) Anticuerpos il-11.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MY191581A (en) Anti-pd-1 antibodies
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12016501763A1 (en) Multispecific antibodies
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
GB2576614B (en) Compositions, uses and methods
IL237852A0 (en) Antibodies against amphigoline, medical preparations containing them and their use
GB201804163D0 (en) Uses, compositions and methods
MX2023006458A (es) Oligosacaridos inmunomoduladores.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.